Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities.

ABSTRACT:

Background

Heterologous oncolytic virus prime-boost vaccination is emerging as a promising cancer immunotherapy to establish potent antitumor immunity. With their natural ability to specifically destroy cancer cells, oncolytic viruses also allow for direct oncolysis and our team has previously demonstrated that they can be used as vaccination adjuvants when co-administered with antigenic peptides. As such, adjuvant oncolytic virus vaccines can easily be tailored to target any antigen, which is particularly important in the context of personalized vaccines against patient-specific mutations. Here, we tested if oncolytic viruses engineered to express the immune-stimulating transgene interleukin-2 have improved vaccination adjuvant potential.

Methods

For this proof-of-concept s

SUBMITTER: Mullins-Dansereau V 

PROVIDER: S-EPMC12090858 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature